Recent anticoagulant use changes thrombolysis assessment, but it should not slow a disabling stroke alert in practice.
Recent DOAC exposure is relative, not automatic, in stroke thrombolysis.
The most useful place to begin is hyperacute acute ischaemic stroke when recent direct oral anticoagulant exposure complicates intravenous thrombolysis. This matters when a patient has sudden unilateral weakness, new speech disturbance, facial droop, acute visual disturbance or another disabling neurological deficit. The practical check is to keep the stroke alert moving while clarifying the anticoagulant name, last dose, missed doses and indication. Recent apixaban, rivaroxaban, edoxaban or dabigatran exposure changes the risk–benefit discussion, but it is not an automatic exclusion.
The next useful topic is renal and cardiovascular physiology: RAAS, eGFR, chronic kidney disease, NSAID use, diabetic atherosclerosis, ACS symptom patterns, oedema and baroreceptor reflexes. For students revising or clinicians explaining blood pressure and kidney function, it gives several clinical anchors. The trauma abstract session is narrower, but helpful for anyone writing acute care research: define the gap, align methods with results, and keep conclusions supported by the work.
Recent DOAC use can complicate thrombolysis without stopping the stroke alert. This is a compact guide to treating anticoagulant exposure as a relative contraindication, clarifying drug and last dose early, and documenting a senior risk–benefit discussion for disabling acute ischaemic stroke.
Raised blood pressure, oedema, reduced urine output or chest pain can be a route into renal and cardiovascular physiology. It links RAAS, eGFR, chronic kidney disease, NSAID risk, diabetic atherosclerosis and ACS symptom patterns without turning the science into isolated facts.
Trauma and acute care research often fails at the abstract stage because the title, knowledge gap, methods, results and conclusion do not align. This suits anyone preparing registry, multicentre, injury prevention or surgical abstracts for review.
When a patient with disabling neurological deficit takes apixaban, rivaroxaban, edoxaban or dabigatran, keep the stroke alert moving. Ask early for the drug name, last dose, missed doses and indication, then escalate and document the thrombolysis reasoning. The detail matters when anticoagulant history threatens to stall assessment.
What should be clarified early when a stroke alert involves DOAC use?
Ask for the exact anticoagulant, last dose, missed doses and indication while the stroke assessment continues.
Does recent DOAC exposure automatically exclude intravenous thrombolysis?
No. It is treated as a relative contraindication that needs senior review, risk–benefit discussion and clear documentation.
What makes a research abstract more credible to reviewers?
A clear gap, aligned methods and results, precise data source, and a conclusion limited to what the findings support.
.svg)